{"id":70747,"date":"2026-05-12T10:39:40","date_gmt":"2026-05-12T10:39:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70747"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"cagrilintide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/cagrilintide\/","title":{"rendered":"Cagrilintide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Cagrilintida?<\/h3>\n<p style=\"margin: 0;\"><strong>Cagrilintide<\/strong> (developmental code AM833) is a 37-amino-acid long-acting synthetic amylin analog developed by Novo Nordisk. It is the lead amylin-class peptide in current metabolic support and the partner compound in the CagriSema combination (cagrilintide + <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a>), now in late-stage Phase 3 trials for obesity and type 2 diabetes. Plasma half-life ~159 hours enables once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1415456-99-3 (cagrilintida; comumente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">An\u00e1logo sint\u00e9tico de amilina de a\u00e7\u00e3o prolongada (pept\u00eddeo acilado de 37 amino\u00e1cidos; agonista do receptor de calcitonina\/amilina; c\u00f3digo de desenvolvimento da Novo Nordisk AM833)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4.981 Da (com acila\u00e7\u00e3o de \u00e1cido di\u00e1cido graxo C20 e ponte dissulfeto intramolecular)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">37 amino\u00e1cidos baseados no arcabou\u00e7o da amilina humana com substitui\u00e7\u00f5es que reduzem a agrega\u00e7\u00e3o formadora de amiloide, uma ponte dissulfeto intramolecular Cys2\u2013Cys7 necess\u00e1ria para a liga\u00e7\u00e3o ao receptor e uma cadeia acilada de \u00e1cido di\u00e1cido graxo C20 anexada via um espa\u00e7ador \u03b3-Glu-OEG-OEG que promove forte liga\u00e7\u00e3o revers\u00edvel \u00e0 albumina s\u00e9rica para a meia-vida semanal. C-terminal amidado.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco amarelado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (geladeira) para estoque de trabalho; \u221220 \u00b0C para armazenamento de longo prazo de frascos fechados. Reconstitu\u00eddo: 2\u20138 \u00b0C, usar em at\u00e9 ~30 dias. Proteger da luz. N\u00e3o congelar e descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para janelas de uso mais curtas. Pept\u00eddeos acilados podem dissolver mais lentamente do que pept\u00eddeos menores n\u00e3o modificados \u2014 permita tempo extra de equil\u00edbrio.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Cagrilintida?<\/h2>\n<p><strong>Cagrilintide<\/strong> is a long-acting synthetic analog of amylin \u2014 a 37-amino-acid pancreatic peptide hormone co-secreted with insulin from beta cells and one of the principal endogenous regulators of postprandial glucose excursion, satiety signalling, and gastric emptying. Endogenous human amylin has a short plasma half-life (~13 minutes), poor pharmacokinetics, and a strong tendency to form amyloid aggregates (the same islet amyloid that accumulates in type 2 diabetic pancreas tissue). Cagrilintide was engineered by Novo Nordisk (developmental code AM833) to overcome each of these limitations: substitutions to reduce aggregation, an intramolecular disulfide bridge preserved for receptor binding, and a C20 fatty-diacid acyl chain attached via a \u03b3-Glu-OEG-OEG spacer that drives strong reversible binding to circulating serum albumin. The combined effect is a plasma half-life of approximately 159 hours (~6.5 days), enabling once-weekly subcutaneous dosing. Cagrilintide has a mature molecular weight of approximately 4,981\u00a0Da including the acyl chain and disulfide bridge. The intramolecular Cys2\u2013Cys7 disulfide is essential for receptor binding \u2014 reduction of this bond converts the peptide into an inactive linear form. The fatty-acid tether is one carbon longer than semaglutide&#8217;s C18 acyl chain, producing the long half-life through the same albumin-binding mechanism. Cagrilintide is the most advanced compound in the renewed wave of amylin-pathway pharmacology, with the lead clinical programme being the <strong>combina\u00e7\u00e3o CagriSema<\/strong> \u2014 cagrilintida 2,4 mg + <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a> 2,4 mg semanal \u2014 que completou os ensaios de Fase 3 REDEFINE-1 (obesidade) e REDEFINE-2 (DM2) com redu\u00e7\u00f5es de peso corporal de aproximadamente 20\u201323% ao longo de 68 semanas. A Cagrilintida \u00e9 <strong>n\u00e3o aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a stand-alone agent or in combination. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Agonismo do Receptor de Amilina em S\u00edtios Centrais e Perif\u00e9ricos<\/h2>\n<p>O que torna a cagrilintida farmacologicamente distinta dos agonistas de GLP-1 \u00e9 que ela atua em um <strong>sistema de receptor completamente diferente \u2014 a fam\u00edlia de receptores de amilina\/calcitonina \u2014 via tr\u00eas mecanismos principais<\/strong> documented in published studies:<\/p>\n<ul>\n<li><strong>Ativa\u00e7\u00e3o do receptor de amilina (AMY1, AMY2, AMY3) \u2014 circuitos de saciedade no tronco cerebral<\/strong> \u2014 Os receptores de amilina s\u00e3o heterod\u00edmeros do receptor de calcitonina (CTR) com as prote\u00ednas modificadoras de atividade do receptor RAMP1, RAMP2 e RAMP3, gerando os subtipos de receptor AMY1, AMY2 e AMY3. O principal local de a\u00e7\u00e3o para a sinaliza\u00e7\u00e3o de saciedade \u00e9 a \u00e1rea postrema no tronco cerebral \u2014 uma das poucas regi\u00f5es do SNC que n\u00e3o possui barreira hematoencef\u00e1lica, permitindo acesso direto pela amilina circulante e an\u00e1logos acilados como o cagrilintida. A ativa\u00e7\u00e3o dos receptores de amilina no tronco cerebral desencadeia proje\u00e7\u00f5es vagais e noradren\u00e9rgicas para o hipot\u00e1lamo, suprimindo a ingest\u00e3o de alimentos em uma escala de tempo por refei\u00e7\u00e3o.<\/li>\n<li><strong>Supress\u00e3o de glucagon e esvaziamento g\u00e1strico retardado<\/strong> \u2014 Al\u00e9m da saciedade central, o cagrilintida reproduz as a\u00e7\u00f5es metab\u00f3licas perif\u00e9ricas da amilina: supress\u00e3o dependente de glicose da secre\u00e7\u00e3o de glucagon pelas c\u00e9lulas alfa pancre\u00e1ticas, redu\u00e7\u00e3o da produ\u00e7\u00e3o hep\u00e1tica de glicose p\u00f3s-prandial e atraso pronunciado do esvaziamento g\u00e1strico. O esvaziamento g\u00e1strico retardado refor\u00e7a a saciedade ao prolongar o sinal de plenitude p\u00f3s-refei\u00e7\u00e3o e reduz a magnitude da excurs\u00e3o de glicose p\u00f3s-prandial. Desenvolve-se taquifilaxia (dessensibiliza\u00e7\u00e3o parcial) do atraso do esvaziamento g\u00e1strico ao longo de semanas de ocupa\u00e7\u00e3o cont\u00ednua do receptor, paralelamente ao padr\u00e3o do eixo GLP-1.<\/li>\n<li><strong>Mecanismo complementar ao GLP-1 \u2014 a l\u00f3gica do CagriSema<\/strong> \u2014 A justificativa cl\u00ednica para combinar o cagrilintida com <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a> baseia-se em mecanismos n\u00e3o sobrepostos. Os agonistas de GLP-1 atuam predominantemente nos neur\u00f4nios POMC do n\u00facleo arqueado hipotal\u00e2mico (regula\u00e7\u00e3o da ingest\u00e3o de alimentos via sistema central de apetite) e nas c\u00e9lulas beta pancre\u00e1ticas (secre\u00e7\u00e3o de insulina dependente de glicose). Os agonistas de amilina atuam predominantemente nos receptores AMY da \u00e1rea postrema do tronco cerebral (refor\u00e7o da saciedade por refei\u00e7\u00e3o) e nas c\u00e9lulas alfa pancre\u00e1ticas (supress\u00e3o de glucagon). Os dois mecanismos s\u00e3o mecanicamente aditivos em vez de sobrepostos, raz\u00e3o pela qual o CagriSema produz efeitos no peso corporal em ensaios de Fase 3 que se aproximam da magnitude do triplo agonista <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">retatrutide<\/a> sem passar pelo receptor GIP ou de glucagon.<\/li>\n<\/ul>\n<p>The C20 fatty-diacid acylation at lysine (analogous to semaglutide&#8217;s C18 modification) drives reversible serum-albumin binding that produces the ~159-hour plasma half-life. The intramolecular Cys2\u2013Cys7 disulfide bridge maintains the bioactive conformation required for AMY-receptor binding \u2014 users must avoid vigorous shaking or freeze-thaw cycles that could disrupt the disulfide. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Cagrilintide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesidade e regula\u00e7\u00e3o do peso corporal<\/strong> \u2014 preclinical DIO (diet-induced obesity) rodent models, body-composition (DEXA\/MRI), food-intake assays, energy-expenditure characterisation; canonical peptide for the renewed amylin-pathway pharmacology programme<\/li>\n<li><strong>Combined cagrilintide + GLP-1 (CagriSema) studies<\/strong> \u2014 estudos comparativos e de combina\u00e7\u00e3o com <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a> em modelos de obesidade e DM2; dissec\u00e7\u00e3o mecanicista dos efeitos complementares versus aditivos versus sin\u00e9rgicos no peso corporal (Enebo et al., Lancet 2021; resultados da Fase 3 do CagriSema)<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 controle glic\u00eamico, supress\u00e3o de glucagon, excurs\u00e3o de glicose p\u00f3s-prandial em modelos de roedores com dieta rica em gordura<\/li>\n<li><strong>Farmacologia do receptor de amilina<\/strong> \u2014 seletividade de subtipos de receptor AMY1\/AMY2\/AMY3, sinaliza\u00e7\u00e3o dependente de RAMP, pot\u00eancia comparativa de agonistas em receptores de calcitonina versus amilina<\/li>\n<li><strong>Brainstem satiety-circuit studies<\/strong> \u2014 ativa\u00e7\u00e3o espec\u00edfica de receptores na \u00e1rea postrema, mapeamento de proje\u00e7\u00f5es vagais e noradren\u00e9rgicas, distin\u00e7\u00e3o dos mecanismos de GLP-1 no n\u00facleo arqueado<\/li>\n<li><strong>Gastric emptying and postprandial physiology studies<\/strong> \u2014 tempo de esvaziamento g\u00e1strico, din\u00e2mica da glicose p\u00f3s-prandial, integra\u00e7\u00e3o do eixo hormonal intestinal<\/li>\n<li><strong>Comparative incretin\/amylin peptide studies<\/strong> \u2014 compara\u00e7\u00e3o com agonista \u00fanico de GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a>), agonista duplo de GIP\/GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a>), e o triplo agonista GLP-1\/GIP\/glucagon (<a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a>) para efeito no peso corporal, controle glic\u00eamico e perfil de efeitos colaterais.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o cagrilintida se encaixa no cen\u00e1rio dos pept\u00eddeos metab\u00f3licos, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> como o parceiro de combina\u00e7\u00e3o CagriSema, <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> como o comparador de receptor duplo, e <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> como o comparador de receptor triplo. Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Cagrilintide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, short-cycle titration studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo estendido, estudos de m\u00faltiplas coortes, menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 2.4\u00a0mg weekly (the CagriSema arm), so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Cagrilintide is a comparatively scarce peptide because of the structural complexity (disulfide bridge + acyl tether) and ongoing clinical development controls, which is reflected in the per-mg price relative to small synthetic peptides. <\/p>\n<h2>Como Compara \u2014 Cagrilintida vs Semaglutida<\/h2>\n<p>Cagrilintida e <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> s\u00e3o as duas metades da combina\u00e7\u00e3o CagriSema \u2014 o principal composto cl\u00ednico da Fase 3 na farmacologia atual da obesidade. Eles atuam em sistemas de receptores completamente diferentes (amilina\/calcitonina vs GLP-1) e produzem efeitos mecanicamente complementares: refor\u00e7o da saciedade pelo eixo da amilina e supress\u00e3o do glucagon de um lado, regula\u00e7\u00e3o do apetite pelo eixo GLP-1 e secre\u00e7\u00e3o de insulina dependente de glicose do outro. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cagrilintide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Fam\u00edlia de receptores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fam\u00edlia de receptores de amilina\/calcitonina (AMY1\/2\/3)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Receptor de GLP-1 (GLP-1R)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">37 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">31 amino\u00e1cidos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Alvo prim\u00e1rio no SNC<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c1rea postrema do tronco cerebral<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\u00facleo arqueado hipotal\u00e2mico (neur\u00f4nios POMC)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeitos perif\u00e9ricos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Supress\u00e3o de glucagon, esvaziamento g\u00e1strico retardado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Secre\u00e7\u00e3o de insulina, supress\u00e3o de glucagon, esvaziamento g\u00e1strico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cadeia de \u00e1cido graxo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 di\u00e1cido + \u03b3Glu-OEG-OEG<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18 di\u00e1cido + \u03b3Glu-AEEA-AEEA<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~159 horas (~6,5 dias)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 horas (~7 dias)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Refer\u00eancia de marca<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Investigacional (AM833; combina\u00e7\u00e3o CagriSema)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito no peso corporal (uso isolado)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~10% (Fase 2 em monoterapia)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15% (ensaios STEP)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Combinado (CagriSema)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\" colspan=\"2\">Redu\u00e7\u00e3o de ~20\u201323% no peso corporal com 2,4 mg + 2,4 mg semanais (REDEFINE-1 Fase 3)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in the amylin axis specifically, cagrilintide is the canonical long-acting peptide. For studies interested in maximal body-weight effect via combination pharmacology, the CagriSema model (cagrilintide + <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a>) \u00e9 a principal refer\u00eancia. Para compara\u00e7\u00e3o com a abordagem de empilhamento de receptores adotada por agonistas m\u00faltiplos de mol\u00e9cula \u00fanica, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> (duplo GLP-1\/GIP) e <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> (triplo GLP-1\/GIP\/glucagon). <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo n\u00e3o aberto, congele a \u221220 \u00b0C. O cagrilintida liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220 \u00b0C por at\u00e9 36 meses. Evite ciclos de congelamento-descongelamento no p\u00f3 liofilizado. Como outros pept\u00eddeos com pontes dissulfeto, a liga\u00e7\u00e3o do cagrilintida ao receptor depende da liga\u00e7\u00e3o intacta Cys2\u2013Cys7 \u2014 manipula\u00e7\u00e3o que rompe a ponte dissulfeto degradar\u00e1 a atividade. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.1\u00a0mL delivers 250\u00a0mcg; ~1.0\u00a0mL delivers a clinical-equivalent 2.4\u00a0mg dose. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> sacuda \u2014 e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa. Pept\u00eddeos acilados dissolvem-se mais lentamente que pept\u00eddeos menores n\u00e3o modificados; n\u00e3o apresse esta etapa. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve estar l\u00edmpida e incolor, sem part\u00edculas vis\u00edveis. <strong>Ap\u00f3s a reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138 \u00b0C e use dentro de 30 dias para estabilidade ideal. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento-descongelamento degradam a integridade do pept\u00eddeo e podem romper a liga\u00e7\u00e3o dissulfeto Cys2\u2013Cys7. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Cagrilintide used for in studies?<\/h3>\n<p>Cagrilintide is used in studies investigating the amylin\/calcitonin receptor axis, brainstem area-postrema satiety circuits, postprandial glucose physiology, gastric emptying, obesity and body-weight regulation, type 2 diabetes preclinical models, and especially combination pharmacology with GLP-1 agonists (the CagriSema study model with <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a>). It is the most-cited long-acting amylin analog in current metabolic-peptide studies. The pharmaceutical-grade cagrilintide sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>O que \u00e9 CagriSema?<\/h3>\n<p>CagriSema \u00e9 o nome de desenvolvimento para a combina\u00e7\u00e3o em dose fixa de <strong>cagrilintide + semaglutide<\/strong> a 2,4 mg + 2,4 mg semanalmente. \u00c9 o principal programa de obesidade em Fase 3 da Novo Nordisk \u2014 os ensaios REDEFINE-1 e REDEFINE-2 relataram redu\u00e7\u00f5es de peso corporal de aproximadamente 20\u201323% ao longo de 68 semanas, colocando o CagriSema na mesma faixa de tamanho de efeito que o triplo-agonista <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">retatrutide<\/a> enquanto segue uma rota mecan\u00edstica completamente diferente (combina\u00e7\u00e3o de dois agonistas de receptor \u00fanico em vez de uma \u00fanica mol\u00e9cula multi-agonista). Cagrilintide \u00e9 a parte da amilina desta combina\u00e7\u00e3o. <\/p>\n<h3>Como o Cagrilintide difere do Semaglutide?<\/h3>\n<p>A diferen\u00e7a fundamental \u00e9 o sistema receptor. Cagrilintide atua na fam\u00edlia de receptores de amilina\/calcitonina (AMY1, AMY2, AMY3) com efeitos centrais prim\u00e1rios na \u00e1rea postrema do tronco cerebral. Semaglutide atua no receptor de GLP-1 com efeitos centrais prim\u00e1rios no n\u00facleo arqueado do hipot\u00e1lamo. Os dois s\u00e3o farmacologicamente complementares, n\u00e3o concorrentes \u2014 sua combina\u00e7\u00e3o no CagriSema produz efeitos aditivos no peso corporal maiores do que qualquer um isoladamente. Ambos s\u00e3o pept\u00eddeos de a\u00e7\u00e3o prolongada com acila\u00e7\u00e3o de \u00e1cido graxo C20\/C18 permitindo dosagem semanal \u00fanica. <\/p>\n<h3>Como o Cagrilintide difere do Tirzepatide?<\/h3>\n<p>Tirzepatide is a single molecule that activates two receptors (dual GLP-1\/GIP agonist). Cagrilintide activates only the amylin\/calcitonin receptor family. For studies interested in body-weight magnitude beyond single-receptor GLP-1, tirzepatide takes the \u201creceptor-stacking in one molecule\u201d approach while CagriSema (cagrilintide + semaglutide) takes the \u201cseparate molecules in combination\u201d approach. The two strategies have produced comparable body-weight effect sizes in their respective Phase 3 trials. <\/p>\n<h3>What is the typical Cagrilintide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 0.16\u00a0mg and increasing through 0.3, 0.6, 1.2, and finally 2.4\u00a0mg maintenance weekly \u2014 the same dose used in the CagriSema combination. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 approximately 1.0\u00a0mL equals a 2.4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>O Cagrilintide \u00e9 aprovado pela FDA?<\/h3>\n<p>No. Cagrilintide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as either a stand-alone agent or in the CagriSema combination. CagriSema Phase 3 trials (REDEFINE-1 obesity, REDEFINE-2 T2DM) have reported positive results but regulatory submission and review remain ongoing as of current literature. <\/p>\n<h3>Como o Cagrilintide deve ser armazenado?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para estoque de trabalho de curto prazo, ou \u221220 \u00b0C para armazenamento de longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, use dentro de 30 dias. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congelamento e descongelamento degradam o pept\u00eddeo e podem interromper a ponte dissulfeto essencial Cys2\u2013Cys7. Proteja da luz direta em todos os momentos. <\/p>\n<h3>Como reconstituir o Cagrilintide?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa (pept\u00eddeos acilados dissolvem-se mais lentamente do que pept\u00eddeos menores n\u00e3o modificados). N\u00e3o <strong>n\u00e3o<\/strong> agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor, sem part\u00edculas vis\u00edveis. Para um frasco de 5 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5 mg\/mL. <\/p>\n<h3>Quais dosagens a MedsBase oferece?<\/h3>\n<p>MedsBase carries Cagrilintide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Por que o Cagrilintide \u00e9 mais caro do que outros pept\u00eddeos?<\/h3>\n<p>Cagrilintide is structurally complex (37 amino acids with an intramolecular disulfide bridge and a fatty-diacid acyl chain) and is a relatively recent compound still under active clinical development by Novo Nordisk. Both factors contribute to higher synthesis cost and constrained supply relative to mature small synthetic peptides like BPC-157 or TB-500. The per-mg price reflects these supply-and-complexity factors rather than any difference in studies utility. <\/p>\n<h3>Can Cagrilintide be paired with Semaglutide in studies?<\/h3>\n<p>Yes \u2014 this is the canonical CagriSema protocol and the lead Phase 3 clinical combination. Cagrilintide and semaglutide act on different receptor families (amylin\/calcitonin vs GLP-1) with non-overlapping central and peripheral mechanisms, producing additive body-weight effects substantially greater than either alone. The clinical fixed-dose ratio is 2.4\u00a0mg cagrilintide + 2.4\u00a0mg semaglutide weekly. <\/p>\n<h3>Does Cagrilintide cause side reported effects?<\/h3>\n<p>Like other satiety-axis peptides, the most consistent finding is gastrointestinal \u2014 nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4\u20138 weeks of continuous dosing as receptor tachyphylaxis develops. Because cagrilintide is the amylin analog and not a GLP-1, the gastrointestinal profile differs from semaglutide in pattern, but the magnitude is comparable in published clinical studies. Long-term safety data continues to accumulate from Phase 3 trials. <\/p>\n<h3>Qual \u00e9 a meia-vida do Cagrilintide?<\/h3>\n<p>Cagrilintide has a plasma half-life of approximately 159 hours (~6.5 days) following subcutaneous administration. The extended half-life is achieved by reversible binding to circulating serum albumin via the C20 fatty-diacid tether at lysine, which protects the peptide from renal clearance. The half-life is comparable to semaglutide&#8217;s ~165 hours, allowing both compounds to be co-dosed weekly in CagriSema studies without divergent pharmacokinetics. <\/p>\n<h3>How long does Cagrilintide take to show effects in preclinical studies?<\/h3>\n<p>Os efeitos farmacodin\u00e2micos agudos no esvaziamento g\u00e1strico e na saciedade por refei\u00e7\u00e3o s\u00e3o detect\u00e1veis dentro de horas ap\u00f3s a primeira dose. Os efeitos no peso corporal em modelos de roedores DIO geralmente se tornam estatisticamente significativos ap\u00f3s 1\u20132 semanas de dosagem semanal e continuam a acumular-se por 8\u201312 semanas. O efeito m\u00e1ximo na composi\u00e7\u00e3o corporal desenvolve-se ao longo de 16\u201324 semanas de dosagem cont\u00ednua, refletindo a trajet\u00f3ria da Fase 3 humana no REDEFINE-1. <\/p>\n<h3>Posso encomendar Cagrilintide para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Cagrilintide para todo o mundo a partir de nossa rede dedicada de envio de pept\u00eddeos. Pedidos exclusivos de pept\u00eddeos qualificam-se para nosso servi\u00e7o de envio de pept\u00eddeos independente. Todos os pedidos s\u00e3o enviados em embalagens com controle de temperatura, com rastreamento completo e cobertos por nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Reenvio Garantido<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Satiety-Axis Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Single GLP-1 agonist \u2014 CagriSema combination partner; canonical glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/pt-br\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista duplo de GLP-1\/GIP \u2014 comparador de empilhamento de receptores em uma mol\u00e9cula<\/li>\n<li><a href=\"\/pt-br\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<li><a href=\"\/pt-br\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/pt-br\/tesamorelin\/\"><strong>Tesamorelina<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore o cen\u00e1rio de combina\u00e7\u00e3o de pept\u00eddeos metab\u00f3licos<\/strong><\/p>\n<p style=\"margin: 0;\">Navegue pela categoria completa <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\"><strong>cat\u00e1logo de pept\u00eddeos<\/strong><\/a>, com compostos de pept\u00eddeos metab\u00f3licos relacionados incluindo <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> (Parceiro CagriSema), <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> (comparador dual GLP-1\/GIP), e <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide\/\">Retatrutida<\/a> (comparador triplo-agonista). Guia comparativo: <a href=\"https:\/\/medsbase.com\/pt-br\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida \u2014 agonista triplo vs dual<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 An\u00e1logo de amilina de a\u00e7\u00e3o prolongada (Novo Nordisk AM833)<br \/>\n\u2705 Agonista de receptor de amilina\/calcitonina<br \/>\n\u2705 Componente da combina\u00e7\u00e3o CagriSema com semaglutida<br \/>\n\u2705 Saciedade no tronco cerebral + supress\u00e3o de glucagon<br \/>\n\u2705 Dosagem semanal (meia-vida de ~159 horas)<\/p>\n<p><strong>Cagrilintide<\/strong> cont\u00e9m composto de pept\u00eddeo sint\u00e9tico.<\/p>","protected":false},"featured_media":70938,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6284,5441],"class_list":["post-70747","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cagrilintide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/70747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=70747"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/70938"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=70747"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=70747"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=70747"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=70747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}